Literature DB >> 1673637

An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene.

B C Langton1, M C Crenshaw, L A Chao, S G Stuart, R W Akita, J E Jackson.   

Abstract

An antigen, immunologically related to the external domain of the c-erbB-2 (HER-2/neu) protein, was found shed into the serum of nude mice bearing tumors that overexpress the c-erbB-2 protein (gp185). Utilizing paired combinations from a panel of monoclonal antibodies (TAbs 250-265), with specificity for extracellular epitopes of gp185, an immunoradiometric assay was developed to quantitate this shed antigen. The immunoradiometric assay detected membrane-bound and soluble gp185 as well as a soluble derivative corresponding in sequence to the extracellular domain of gp185 (designated gp75). This recombinantly expressed gp75 was immunoaffinity purified and used to generate a standard curve from which serum samples were quantitated. Increases in antigen levels measured in the sera of tumor-bearing nude mice correlated with both overexpression of the c-erbB-2 protein and increased tumor volume. Positive sera were obtained from mice given implants of NIH3T3 cells transfected with c-erbB-2 complementary DNA (NIH3T3t), or ovarian (SK-OV-3) or breast (MDA-MB-361) tumor cell lines overexpressing the c-erbB-2 protein. In mice bearing NIH3T3t tumors, increases in tumor volume from 80 to 9000 mm3 resulted in levels of shed antigen from 8 to greater than 1000 ng/ml gp75 equivalents. Sera from mice with c-erbB-2-negative tumors or tumors overexpressing the epidermal growth factor receptor were negative in the assay. This assay, and the quantitation of shed antigen levels, may have diagnostic or monitoring utility in cancers, such as breast and ovarian, in which the c-erbB-2 protein is overexpressed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1673637

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase.

Authors:  A Esparís-Ogando; E Díaz-Rodríguez; A Pandiella
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

2.  The cellular response to neuregulins is governed by complex interactions of the erbB receptor family.

Authors:  D J Riese; T M van Raaij; G D Plowman; G C Andrews; D F Stern
Journal:  Mol Cell Biol       Date:  1995-10       Impact factor: 4.272

3.  Increased serum concentrations of growth factor receptors and Neu in workers previously exposed to asbestos.

Authors:  N Lahat; P Froom; E Kristal-Boneh; C Cohen; Y Lerman; J Ribak
Journal:  Occup Environ Med       Date:  1999-02       Impact factor: 4.402

4.  MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo.

Authors:  Y Liu; D el-Ashry; D Chen; I Y Ding; F G Kern
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

5.  Analysis of c-erbB2 protein content of human glioma cells and tumor tissue.

Authors:  H H Engelhard; M Wolters; P S Criswell
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

6.  Determination of ErbB2 protein in breast cancer tissues by different methods. Relationships with other biological parameters.

Authors:  A Piffanelli; R Dittadi; L Catozzi; M Gion; G Capitanio; M C Gelli; A Brazzale; R Malagutti; D Pelizzola; A Menegon; G Giovannini; G Gardini
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

7.  A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells.

Authors:  G K Scott; R Robles; J W Park; P A Montgomery; J Daniel; W E Holmes; J Lee; G A Keller; W L Li; B M Fendly
Journal:  Mol Cell Biol       Date:  1993-04       Impact factor: 4.272

8.  C-erbB-2 protein in the sera of breast cancer patients.

Authors:  T Narita; H Funahashi; Y Satoh; H Takagi
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

9.  Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses.

Authors:  R Lupu; R Colomer; B Kannan; M E Lippman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

10.  Isolation of the intact molecule and ectodomain of C-erbB-2 oncoprotein from SK-BR-3 cells and development of immunoassays on microplate.

Authors:  J T Wu; P Zhang; B W Lyons; L H Wu
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.